Semi-random LV-IL2RG insertions and the consequent safety concerns are well described, particularly with strong enhancers as reported in the lentiviral gene therapy for cerebral adrenoleukodystrophy (Servick K. Gene therapy clinical trial halted as cancer risk surfaces. This evidence concerns the gene IL2RG and cancer.